Loading market dashboard
Veracyte, Inc.
VCYTHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
On the heels of the landmark [url="]OPTIMA trial[/url] readout presented at the ASCO Annual Meeting, Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostic
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BreastCancer--Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
[url="]Veracyte, Inc.[/url] (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the [url="]ENZAMET trial[/url] presented at the
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Delivers Practice-Changing Evidence that Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemo.
Veracyte is evolving into a multi-cancer clinical decision-making platform, leveraging evidence, payer coverage, and workflow integration for durable growth. Q1 2026 results showed 21% revenue growth, expanding gross margins (up to 76% non-GAAP), and strong operating leverage, with raised 2026 guidance and robust cash generation. Medicare coverage for TrueMRD in muscle-invasive bladder cancer and the upcoming Prosigna LDT launch in breast cancer expand VCYT's addressable market and reinforce its evidence-driven moat.
VCYT gains from strong Afirma and Decipher test growth, but macro pressures and competition pose risks. See what may shape its next move.
Today we feature studies to be presented at the year's most important cancer conference, the upcoming American Society of Clinical Oncology meeting in Chicago, all with the potential to be practice-changing.
VCYT jumps 65.8% in a year as Afirma and Decipher volumes surge, guidance lifts, and TrueMRD nears launch with $439M cash and no debt.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will be presented at the 2026 ASCO Annual Meeting. This includes results from the OPTIMA and ENZAMET trials. Professor Iain Macpherson, one of the principal i.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the company will be participating in the following investor conferences. William Blair 46th Annual Growth Stock Conference – Chicago, IL Presentation on Tuesday, June 2nd at 2:00 p.m. Central Time 2026 Jefferies Global Healthcare Conference – New York, NY Fireside chat on Thursday, June 4th at 8:10 a.m. Eastern Time Live audio webcasts of the company's presentations will be available by visiting Ver.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BladderCancer--Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer.
On May 13, 2026, Veracyte Inc (VCYT) shares fell 3.3%, bringing the current price to $38.26. The stock has experienced a 52-week range of $22.61 to $50.71, show
Veracyte grew revenue by 21% in Q1 and saw earnings per share quadruple from last year, as margins ballooned. Sales for the company's main prostate and thyroid cancer-detecting tests continue to grow by double-digit rates.
After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript
Veracyte (VCYT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.31 per share a year ago.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. “We had a strong start to the year, with Decipher and Afirma volume growth surpassing expectations and exceeding our profitability targets,” said Marc Stapley, Veracyte's CEO. “Our growing clinical evidence continues to set us apart, and this quarter strengthened it even further. We believe we are approac.
The average of price targets set by Wall Street analysts indicates a potential upside of 39.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #AUA26--Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers.
Veracyte (VCYT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VCYT broke out above the 50-day moving average, suggesting a short-term bullish trend.
AEGON ASSET MANAGEMENT UK Plc lifted its holdings in shares of Veracyte, Inc. (NASDAQ: VCYT) by 19.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 489,418 shares of the biotechnology company's stock after purchasing an additional
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be av.
Veracyte (NASDAQ: VCYT - Get Free Report) and Advanced Biomedical Technologies (OTCMKTS:ABMT - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Profitability This table compares Veracyte and Advanced Biomedical
VCYT rides on Afirma and Decipher growth with strong earnings beat and liquidity, but macro pressures and rising competition cloud its near-term outlook.
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #CancerDiagnostics--Veracyte Names Kevin Haas as Chief Development and Technology Officer.
Bamco Inc. NY lowered its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 26.4% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 645,621 shares of the biotechnology company's stock after selling 231,579 shares during the quarter. Bamco
